221 related articles for article (PubMed ID: 25813264)
21. Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial.
Tanaka A; Shimabukuro M; Okada Y; Taguchi I; Yamaoka-Tojo M; Tomiyama H; Teragawa H; Sugiyama S; Yoshida H; Sato Y; Kawaguchi A; Ikehara Y; Machii N; Maruhashi T; Shima KR; Takamura T; Matsuzawa Y; Kimura K; Sakuma M; Oyama JI; Inoue T; Higashi Y; Ueda S; Node K;
Cardiovasc Diabetol; 2017 Apr; 16(1):48. PubMed ID: 28403850
[TBL] [Abstract][Full Text] [Related]
22. Empagliflozin: a sodium-glucose cotransporter 2 inhibitor for treatment of type 2 diabetes.
Dixit D; Yoon Y; Volino LR; Mansukhani RP
Am J Health Syst Pharm; 2015 Nov; 72(22):1943-54. PubMed ID: 26541949
[TBL] [Abstract][Full Text] [Related]
23. Empagliflozin (Jardiance) for diabetes.
Med Lett Drugs Ther; 2014 Oct; 56(1453):99-100. PubMed ID: 25296258
[No Abstract] [Full Text] [Related]
24. Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis.
Liakos A; Karagiannis T; Athanasiadou E; Sarigianni M; Mainou M; Papatheodorou K; Bekiari E; Tsapas A
Diabetes Obes Metab; 2014 Oct; 16(10):984-93. PubMed ID: 24766495
[TBL] [Abstract][Full Text] [Related]
25. The SGLT2 inhibitor empagliflozin ameliorates early features of diabetic nephropathy in BTBR ob/ob type 2 diabetic mice with and without hypertension.
Gembardt F; Bartaun C; Jarzebska N; Mayoux E; Todorov VT; Hohenstein B; Hugo C
Am J Physiol Renal Physiol; 2014 Aug; 307(3):F317-25. PubMed ID: 24944269
[TBL] [Abstract][Full Text] [Related]
26. Single-pill combination therapy for type 2 diabetes mellitus: linagliptin plus empagliflozin.
Aronson R
Curr Med Res Opin; 2015 May; 31(5):901-11. PubMed ID: 25775379
[TBL] [Abstract][Full Text] [Related]
27. Empagliflozin added to metformin and sulfonylurea therapy in patients with sub-optimally controlled type 2 diabetes mellitus.
Lewin AJ; Frías JP
Expert Opin Pharmacother; 2015 Apr; 16(5):781-4. PubMed ID: 25644093
[TBL] [Abstract][Full Text] [Related]
28. The cardiovascular benefits of empagliflozin: SGLT2-dependent and -independent effects.
Vettor R; Inzucchi SE; Fioretto P
Diabetologia; 2017 Mar; 60(3):395-398. PubMed ID: 28074254
[No Abstract] [Full Text] [Related]
29. [Novel therapeutic options in patients with type 2 diabetes and high cardiovascular risk].
Laubner K; Seufert J
Dtsch Med Wochenschr; 2016 Jun; 141(11):757-60. PubMed ID: 27176455
[TBL] [Abstract][Full Text] [Related]
30. Cardiovascular outcomes of sodium-glucose cotransporter 2 inhibitors: A comprehensive review of clinical and preclinical studies.
Ghosh RK; Bandyopadhyay D; Hajra A; Biswas M; Gupta A
Int J Cardiol; 2016 Jun; 212():29-36. PubMed ID: 27017118
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of the pharmacokinetics, pharmacodynamics and clinical efficacy of empagliflozin for the treatment of type 2 diabetes.
Tomlinson B; Hu M; Zhang Y; Chan P; Liu ZM
Expert Opin Drug Metab Toxicol; 2017 Feb; 13(2):211-223. PubMed ID: 27817207
[TBL] [Abstract][Full Text] [Related]
32. Tofogliflozin: the road goes ever on.
Pafili K; Papanas N
Expert Opin Pharmacother; 2014 Jun; 15(9):1197-201. PubMed ID: 24787286
[TBL] [Abstract][Full Text] [Related]
33. Tofogliflozin: a highly selective SGLT2 inhibitor for the treatment of type 2 diabetes.
Rosenwasser RF; Rosenwasser JN; Sutton D; Choksi R; Epstein B
Drugs Today (Barc); 2014 Nov; 50(11):739-45. PubMed ID: 25525634
[TBL] [Abstract][Full Text] [Related]
34. Sodium-glucose cotransporter 2 inhibition and cardiovascular risk reduction in patients with type 2 diabetes: the emerging role of natriuresis.
Rajasekeran H; Lytvyn Y; Cherney DZ
Kidney Int; 2016 Mar; 89(3):524-6. PubMed ID: 26880444
[TBL] [Abstract][Full Text] [Related]
35. Empagliflozin on top of metformin treatment improves arterial function in patients with type 1 diabetes mellitus.
Lunder M; Janić M; Japelj M; Juretič A; Janež A; Šabovič M
Cardiovasc Diabetol; 2018 Dec; 17(1):153. PubMed ID: 30509271
[TBL] [Abstract][Full Text] [Related]
36. Impact of empagliflozin in patients with diabetes and heart failure.
Pham D; Albuquerque Rocha N; McGuire DK; Neeland IJ
Trends Cardiovasc Med; 2017 Feb; 27(2):144-151. PubMed ID: 27612553
[TBL] [Abstract][Full Text] [Related]
37. Empagliflozin: a review of its use in patients with type 2 diabetes mellitus.
Scott LJ
Drugs; 2014 Oct; 74(15):1769-84. PubMed ID: 25274537
[TBL] [Abstract][Full Text] [Related]
38. Sodium-Glucose Cotransporter 2 Inhibitors in the Treatment of Type 2 Diabetes Mellitus.
Vivian E
Diabetes Educ; 2015 Dec; 41(1 Suppl):5S-18S. PubMed ID: 26450220
[TBL] [Abstract][Full Text] [Related]
39. Empagliflozin/Linagliptin: A Review in Type 2 Diabetes.
Kim ES; Deeks ED
Drugs; 2015 Sep; 75(13):1547-57. PubMed ID: 26323340
[TBL] [Abstract][Full Text] [Related]
40. Practical considerations for the use of sodium-glucose co-transporter type 2 inhibitors in treating hyperglycemia in type 2 diabetes.
Lam KS; Chow CC; Tan KC; Ma RC; Kong AP; Tong PC; Tsang MW; Chan TM; Tang SC; Lee KK; So WY; Tomlinson B
Curr Med Res Opin; 2016 Jun; 32(6):1097-108. PubMed ID: 26933918
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
